Literature DB >> 35026413

External control arms in oncology: current use and future directions.

P S Mishra-Kalyani1, L Amiri Kordestani2, D R Rivera3, H Singh4, A Ibrahim2, R A DeClaro4, Y Shen5, S Tang5, R Sridhara3, P G Kluetz4, J Concato6, R Pazdur4, J A Beaver4.   

Abstract

Although randomized control trials allow for a comparison of treatment arms with minimal concern for confounding by known and unknown factors, a randomized study is not feasible in certain disease settings. When a randomized design is not possible, incorporating external control data into the study design can be an effective way to expand the interpretability of the results of an experimental arm by introducing the ability to carry out a formal or an informal comparative analysis. This paper provides an introduction to the concepts of external controls in oncology trials, followed by a review of relevant and current research on this topic. The paper also focuses on general considerations for designing a trial that may incorporate external control data, followed by case studies of the marketing applications submitted to the Food and Drug Administration that included external control data. Published by Elsevier Ltd.

Entities:  

Keywords:  Food and Drug Administration; external controls; real-word data

Mesh:

Year:  2022        PMID: 35026413     DOI: 10.1016/j.annonc.2021.12.015

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  6 in total

Review 1.  A Review of Causal Inference for External Comparator Arm Studies.

Authors:  Gerd Rippin; Nicolás Ballarini; Héctor Sanz; Joan Largent; Chantal Quinten; Francesco Pignatti
Journal:  Drug Saf       Date:  2022-07-27       Impact factor: 5.228

Review 2.  Novel Clinical Trial Designs in Neuro-Oncology.

Authors:  Anurag Saraf; Lorenzo Trippa; Rifaquat Rahman
Journal:  Neurotherapeutics       Date:  2022-08-15       Impact factor: 6.088

3.  Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer.

Authors:  Sanjay Popat; Stephen V Liu; Nicolas Scheuer; Grace G Hsu; Alexandre Lockhart; Sreeram V Ramagopalan; Frank Griesinger; Vivek Subbiah
Journal:  Nat Commun       Date:  2022-06-17       Impact factor: 17.694

Review 4.  Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows.

Authors:  Marina Elena Cazzaniga; Serena Capici; Nicoletta Cordani; Viola Cogliati; Francesca Fulvia Pepe; Francesca Riva; Maria Grazia Cerrito
Journal:  J Clin Med       Date:  2022-08-12       Impact factor: 4.964

Review 5.  Implications of Oncology Trial Design and Uncertainties in Efficacy-Safety Data on Health Technology Assessments.

Authors:  Dario Trapani; Kiu Tay-Teo; Megan E Tesch; Felipe Roitberg; Manju Sengar; Sara C Altuna; Michael J Hassett; Armando A Genazzani; Aaron S Kesselheim; Giuseppe Curigliano
Journal:  Curr Oncol       Date:  2022-08-16       Impact factor: 3.109

Review 6.  A Causal Framework for Making Individualized Treatment Decisions in Oncology.

Authors:  Pavlos Msaouel; Juhee Lee; Jose A Karam; Peter F Thall
Journal:  Cancers (Basel)       Date:  2022-08-14       Impact factor: 6.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.